Core Viewpoint - The company is set to invest 420 million yuan in a new biomanufacturing facility for APIs and health dietary supplements in Inner Mongolia, which will enhance its production capabilities and market position [1] Investment Project Details - The total investment for the project is 420 million yuan, with approximately 300 million yuan allocated for fixed asset investment [1] - The project aims to leverage the geographical advantages and resource endowments of Tokto County, facilitating the establishment of a large-scale, standardized production base [1] Strategic Benefits - The investment will create favorable conditions for efficient R&D and production activities, thereby improving operational efficiency [1] - Abundant local energy resources are expected to help the company reduce production costs and expand profit margins [1] - Upon completion, the project will enhance the company's industrial chain layout, solidify its market competitiveness, and strengthen its core profitability and sustainable development capabilities [1]
拓新药业拟4.2亿元投建原料药及健康膳食补充剂生物制造基地建设项目